Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 24 of 1,261
  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12377026

    Dental adhesive material kit

    KURARAY NORITAKE DENTAL INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  3. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  4. US 12378560

    Sequence multiplicity within spherical nucleic acids

    Northwestern University · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  5. US 12378277

    SGLTS/DPP4 inhibitor and application thereof

    DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  6. US 12378201

    Histone demethylase inhibitors for treating cancers

    The Board of Regents of the University of Texas System · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  7. US 12378557

    Treatment of sepsis with PCSK9 and LDLR modulators

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  8. US 12378540

    Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

    DENALI THERAPEUTICS INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  9. US 12377135

    GHRH antagonists for use in a method of treating sarcoidosis

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  10. US 12378286

    Methods and compositions useful for inhibiting growth of certain bacteria

    The Regents of the University of California · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  11. US 12378337

    Lipid nanodiscs solubilized through poly(acrylic acid-co-styrene) copolymers

    The Regents of the University of California · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  12. US 12377159

    Steroids and protein-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  13. US 12377155

    Bicyclic peptide ligands specific for PSMA

    BicycleRD Limited · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  14. US 12377090

    Methods for treating neutropenia

    X4 Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  15. US 12377093

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  16. US 12377186

    Antimicrobial biopolymer compositions, methods of synthesis, and applications of use

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  17. US 12378231

    Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof

    APOGEE PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  18. US 12378288

    Multimeric bicyclic peptide ligands

    BicycleTx Limited · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  19. US 12378553

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  20. MX 2025007399

    PROTEIN-BASED CONJUGATION CARRIERS

    ABLYNX NV [BE] · Granted Aug 1, 2025 · Expires Jul 27, 2045

    granted
  21. CN 120418289

    Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

    ASTELLAS PHARMA EUROPE B V · Granted Aug 1, 2025 · Expires Jul 27, 2045

    granted
  22. WO 2025159142

    COMPOSÉ HÉTÉROCYCLIQUE POUR INDUIRE LA DÉGRADATION DE LA PROTÉINE KRAS

    ASTELLAS PHARMA INC [JP] · Granted Jul 31, 2025 · Expires Jul 26, 2045

    granted
  23. US 12371445

    Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same

    The Regents of the University of California · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  24. US 12371499

    Method of treating cancer using anti-AV8 antibodies

    The Regents of the University of California · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.